Abstract
Golgi-protein 73 (GP73) is highly expressed in hepatocellular carcinoma (HCC) and serves as a secretory biomarker for disease progression. This study identifies a novel functional role for GP73 in promoting HCC metastasis by interacting with vimentin. GP73 facilitates PP1A-mediated dephosphorylation of vimentin at Serine 56, promoting its polymerization. This polymerization effectively shields vimentin from TRIM56-mediated ubiquitin/proteasome-dependent degradation, stabilizing the mesenchymal cytoskeleton. Furthermore, the antidepressant Clomipramine was identified as a potent inhibitor of GP73-mediated vimentin polymerization, significantly reducing metastasis in vivo. These findings establish GP73 as a key regulator of vimentin stability and suggest that serum GP73 (sGP73) can serve as a companion diagnostic for vimentin-targeted therapies in metastatic HCC.
Introduction
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, primarily due to its high rate of metastasis. Golgi-protein 73 (GP73) has long been used as a serum biomarker for HCC, but its functional role in cancer spread remained poorly defined. Metastasis is often driven by the Epithelial-Mesenchymal Transition (EMT), where vimentin plays a critical role in providing structural integrity to migratory cells. This research investigates how GP73 regulates vimentin to fuel HCC progression.
Methods and Discovery
To identify GP73's molecular partners, researchers used LC-MS/MS proteomics, which pinpointed vimentin as a key interactor. This was confirmed through Co-Immunoprecipitation (Co-IP) assays.
The study also employed Structural Illumination Microscopy (SIM) for high-resolution imaging of vimentin filaments and biochemical assays to analyze polymerization states. Molecular docking was used to screen FDA-approved compounds for their ability to disrupt vimentin assembly.
Results
The GP73-Vimentin-PP1A Axis
GP73 acts as a scaffold that recruits the phosphatase PP1A to dephosphorylate vimentin at S56. This dephosphorylation is the key trigger for vimentin polymerization. Crucially, polymerization protects vimentin from being targeted by the E3 ubiquitin ligase TRIM56, which can only degrade monomeric vimentin. Thus, GP73 stabilizes the vimentin network by "shielding" it from the proteasome.
Functional Impact and Therapeutic Targeting
Functional assays demonstrated that GP73 expression is essential for vimentin-mediated cell migration. In metastatic HCC cell lines, silencing GP73 significantly impaired migration.
Screening identified Clomipramine, an FDA-approved antidepressant and 5-HTR agonist, as a potent inhibitor of vimentin polymerization. In mouse models, Clomipramine effectively reduced lung metastasis and showed synergistic effects when combined with the standard drug Sorafenib.
Clinical Significance
In patient cohorts, GP73 and vimentin levels showed a strong positive correlation ($r = 0.7440$), and high expression of both was linked to poor survival. Serum GP73 (sGP73) levels effectively predicted high tissue vimentin (AUC = 0.8048), suggesting its utility as a companion diagnostic tool.
Discussion
This study elucidates a novel mechanism where GP73 stabilizes vimentin to promote HCC metastasis. The discovery that Clomipramine can disrupt this process provides a promising avenue for drug repurposing in cancer therapy. While further clinical trials are needed, the correlation between serum GP73 and tissue vimentin offers a practical method for identifying patients who might benefit from these targeted interventions.
Summary updated